Avapritinib
Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)
Explore 8 assets in Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07028073CT.gov A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Avapritinib (this asset) | The First Affiliated Hospital of Soochow University | P1/2 | CCC · 48 |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Idarubicin | Bruno C. Medeiros | P2 | BBB |
| Fludarabine | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | BBB |
| Cytarabine | Alice Mims | P3 | BBB |
| Etoposide | Alice Mims | P3 | BBB |
| Azacitidine | The First Affiliated Hospital of Soochow University | P2 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P3 | BBB |
| Nivestim | Rutgers, The State University of New Jersey | P3 | BBB |
+42 more in the Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) cohort
Other indications for Avapritinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastrointestinal Stromal Tumor | — | P3 | BB · 67 |
| Aggressive Systemic Mastocytosis | — | P2 | BB · 64 |
| Systemic Mastocytosis With An Associated Clonal Hematologic Non-Mast Cell Lineage Disease | — | P2 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Avapritinib in Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22). Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/avapritinib-acute-myeloid-leukemia-with-abnormal-bone-marrow-eosinophils-inv16p13q22-or-t1616p13q22
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →